Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
Stopped The study was interrupted early and terminated when only 26 out of 80 patients were enrolled due to new clinical study results indicating that the current study would not be informative.
Conditions
- Diabetes Mellitus, Type 1
- Prediabetic State
Interventions
- DRUG: Alum-GAD
- DRUG: Vitamin D3
Sponsor
Lund University
Collaborators